Cargando…
A Multicompartment Mathematical Model Based on Host Immunity for Dissecting COVID-19 Heterogeneity
Background: As of early August 2021, more than 190 million people have developed coronavirus disease (COVID-19), a pandemic that has killed approximately 4 million people. Caused by acute respiratory syndrome coronavirus 2 (SARS-CoV-2), COVID-19 exhibited a highly variable clinical course, ranging f...
Autores principales: | Wu, Jianghua, Mei, Heng, Li, Jianwei, Zhang, Jingpeng, Tang, Lu, Du, Mengyi, Li, Fangting, Hu, Yu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Hematology. Published by Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701520/ http://dx.doi.org/10.1182/blood-2021-149381 |
Ejemplares similares
-
Vaccine Efficacy after Rituximab Exposure: First Interim Analysis of Virtue Project on Behalf of West Midlands Research Consortium, UK
por: Shields, Adrian M, et al.
Publicado: (2021) -
Characterization of the Early Humoral and Cellular Response Developed in Oncohematological Patients Post-Vaccination with One Dose Against COVID-19
por: Corona De Lapuerta, Magdalena, et al.
Publicado: (2021) -
Time Since Last Anti-CD20 Treatment Is a Major Determinant of Sars-Cov-2 Vaccine Response in a Large Cohort of Patients with B-Cell Lymphoma
por: Shree, Tanaya, et al.
Publicado: (2021) -
Multi-Arm Trial of Inflammatory Signal Inhibitors (MATIS) for Hospitalised Patients with Mild or Moderate COVID-19 Pneumonia: A Structured Summary of a Study Protocol for a Randomised Controlled Trial
por: Charania, Asad, et al.
Publicado: (2021) -
Clinical and Immunological Assessment of Patients with Sars-Cov-2 Infections
por: Singh, Aditi, et al.
Publicado: (2021)